Roots Analysis is pleased toannounce the publication of its recent study, titled, “LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market,2020-2030: Focus on Active Pharmaceutical Ingredients and Finished DosageForms, 2020-2030.”
The report features an extensive study of thecurrent landscape and future opportunities related to contract services formicrobiome therapeutics. The study features an in-depth analysis, highlightingthe capabilities of a diverse set of contract service providers, including CMOsand CDMOs. Amongst other elements, the report includes:
§ Adetailed review of the overall landscape of companies offering contractservices for manufacturing of microbiome therapeutics.
§ Alist of companies with in-house manufacturing facilities for microbiometherapeutics.
§ Elaborateprofiles of key industry players (large and mid-sized companies, establishedbefore 2000) based in North America, Europe and Asia-Pacific.
§ Anassessment of microbiome contract manufacturing capability in differentregions.
§ Alist of nearly 50 microbiome-focused drug developers that are anticipated topartner with contract manufacturers.
§ Adetailed clinical trial analysis of more than 150 completed, ongoing andplanned studies of various microbiome therapeutics sponsored by both industryand non-industry players.
§ Anestimate of the overall, installed capacity for manufacturing of microbiometherapeutics, taking into consideration the capabilities of various stakeholders.
§ Aninformed estimate of the annual clinical demand for microbiome therapeutics,taking into account the target patient population in ongoing and plannedclinical trials of microbiome therapeutics, sponsored by both industry andnon-industry players.
§ Aqualitative analysis, highlighting the various factors that need to be takeninto consideration by microbiome therapeutics developers while deciding whetherto manufacture their respective products in-house or engage the services of aCMO.
§ Areview of the varied microbiome-focused initiatives of big pharma players.
A detailed market forecast,featuring analysis of the current and projected future opportunity across keymarket segments (listed below):
§ Type of ProductManufactured
§ Active PharmaceuticalIngredients (APIs)
§ Finish DrugFormulations (FDFs)
§ Type of Type ofFormulation
§ Solid Formulations
§ Oral Liquids
§ Injectables
§ Others
§ Scale of Operation
§ Clinical
§ Commercial
§ Company Size
§ Small-sized
§ Mid-sized
§ Large
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia-Pacific and Restof the World
Keycompanies covered in the report
§ Biose®
§ BJP Laboratories
§ Capsugel (acquired byLonza)
§ Cerbios-Pharma
§ Cobra Biologics(acquired Cognate Bioservices)
§ Inpac Probiotics
§ ParagonBioservices (a unit of Catalent Biologics)
§ UAS Labs
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Other Recent Offerings
1. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
2. Antibody Contract Manufacturing Market, 2020 – 2030
3. The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targetingdrugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
